- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
Panelists discuss how data from FRESCO-2 and other trials position fruquintinib as a strong third-line option compared with regorafenib and FTD/TPI.
Panelists turn to the FRESCO-2 trial, which established fruquintinib as another evidence-based option for patients with refractory metastatic colorectal cancer. The trial findings showed significant overall survival benefits, positioning the drug as an important addition to the treatment armamentarium.
They compare these outcomes with the CORRECT trial on regorafenib and data on trifluridine/tipiracil (FTD/TPI), highlighting nuanced differences in efficacy and toxicity profiles that guide personalized decision-making.
The discussion underscores the importance of tailoring therapy choices to individual patient needs and tolerability, given the availability of multiple validated agents.
